Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. It operates through the BioScience and BioIndustrial segments. The BioScience segment works on enzymes and performance microorganisms; and collaborates with industrial partners. The BioIndustrial segment deals with the bioproduct and cosmetics businesses. The company was founded by Holger Zinke, Jüngen Eck, and Hans Günter Gassen on September 22, 1993 and is headquartered in Zwingenberg, Germany.

Guangzhou Keren Bioengineering Co., Ltd., established on 2006-06-05, The business scope includes the wholesale of feed additives;Feed Additives Retail;Biotechnology Development Services;Biotechnology Transfer Services;Import and export(Excluding franchised products);Technology Import and Export;Medical Research and Experimental Development;Feed additives,Additive premix feed production;

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.

Merz Pharma GmbH & Co. KGaA is an innovative and international healthcare company with its own research and development department. It focuses on drugs for the treatment of illness in the fields of neurology and psychiatry. The company is bundling the activities of its subsidiaries Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, and Merz Hygiene, with products ranging from prescription drugs and OTC products for health and wellness, materials for dentists and dental technicians to hygienic products for medical disinfection and cleaning.\nThe units of Merz Group Services, the fith Merz subsidiary, include Human Resources, Supply Chain/Purchasing, Information Technology (IT), Technical Operations and Finances/Controlling.

Exoxemis, Inc. is an American private company. The firm provides research and development services.\nThe company says this about itself: Exoxemis holds a number of method and composition patents throughout the world, and a number of patents are currently pending. In addition, the company has registered Zempia and has pending trademarks throughout the world. An exclusive licensing agreement is available for Zempia for further study and testing with applications in a number of potential markets: for use in preventing sepsis, in conjunction with large joint implants; urinary catheters; dental implants and oral surgeries; for use in the ER, in wound treatments, colorectal, HEENT, Plastics/Burn..really in any surgery or condition involving an open wound or normal flora environment that is susceptible to infection. This includes skin care, dermatology, even cosmetics.

Decoy Biosystems is a biotechnology company developing a novel and potentially best in class, multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. Decoy is dedicated to enhancing the expanding curative cancer immunology for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for approximately 90 percent of all cancer deaths.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Sandia Corp. is an American private company located in Albuquerque, NM, with domestic subsidiaries. The firm provides science-based technological research services.

Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.

GeneCare Research Institute Co., Ltd. engages in the research, development, and drug discovery of treatments in the field of cancer, inflammation, hepatic carcinoma and rheumatism. It provides the distribution services for its products through their direct customers, which includes pharmaceutical companies and clinical-related companies. The company was founded by Yasuhiro Furuichi on December 20, 2000 and is headquartered in Kamakura, Japan.

Kumiai Chemical Industry Co., Ltd. engages in the manufacture and sale of agricultural chemicals such as insecticides, fungicides, herbicides, and other pesticides. It operates through the Agricultural Chemicals and Agriculture-Related, Chemical Products, and Others. The Agricultural Chemicals and Agriculture-Related segment manufactures and sells agrochemicals such as insecticides, fungicides, and herbicides and greening materials. It also provides maintenance services for golf courses. The Chemical Products segment produces and markets chlorotoluene and chloroxylene type chemicals, fine chemicals, and styrofoam. The Others segment includes leasing, power sale and generation, construction, printing, logistics, and information service businesses. The company was founded in 1928 and is headquartered in Tokyo, Japan.

Shanghai Putianxin Biotechnology Co., Ltd., established on 2007-04-20, The scope of business includes technical consulting in the field of biotechnology,technology development,technology transfer,Technical Services,Technical Training,Technical Contracting,technology intermediary,technology investment;Chemical Products(In addition to dangerous goods)promotion of. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Chongcheng Investment Management (Shanghai) Co., Ltd., established on 2015-12-25, Business scope includes investment management,Business Consulting,Investment Advisory,Business Management Consulting,Corporate Image Planning,Enterprise Marketing Planning,Planning of cultural and artistic exchange activities,account Serive,daily necessities,crafts(Remove cultural relics),electronic product,Mechanical equipment and accessories,Computers and Accessories,knitted goods,Toy,apparel,shoes and hats,cosmetic,Wholesale of daily necessities,import and export,commission agent(except auction)and related services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

Kunming Sino Pharmaceutical Co., Ltd., established on 1998-06-24, Business scope includes mixture,oral liquid,tablet,hard capsule,Granules,API(Amlodipine mesylate,rehabilitation new,Erigeron extract),pill(Pellets),tincture;medical instruments(Class II6854-11rinse,ventilation,pressure relief device)production,Sales,Technology Transfer and Consulting;Goods and technology import and export business(Hazardous Chemicals,Except for ammonia-related refrigeration industry and national restricted prohibited products)(It is not allowed to engage in restricted industries in the zone’s industrial policies in the Economic Development Zone.,Prohibited industries)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)